Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
The Oncology Institute Inc (TOIIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TOIIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -52.86% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.16 | 52 Weeks Range 0.01 - 0.20 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.20 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -602.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.96% | Operating Margin (TTM) -9.49% |
Management Effectiveness
Return on Assets (TTM) -17.66% | Return on Equity (TTM) -277.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 66946108 |
Shares Outstanding - | Shares Floating 66946108 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
The Oncology Institute Inc
Company Overview
History and Background
The Oncology Institute, Inc. (TOI) was founded with the goal of expanding access to cancer care in community settings. They primarily operate through a network of community-based cancer centers. TOI became public through a business combination with DFP Healthcare Acquisitions Corp., a special purpose acquisition company (SPAC), completed in August 2021.
Core Business Areas
- Community-Based Cancer Care: Provides comprehensive, integrated cancer care services, including medical oncology, radiation oncology, hematology, and other related services in local community settings.
- Value-Based Care Programs: Participates in various value-based care programs that focus on improving patient outcomes and reducing healthcare costs. They leverage technology and data analytics to optimize care delivery and manage patient populations effectively.
Leadership and Structure
TOI has a management team led by its CEO and other key executives overseeing various functional areas, such as operations, finance, and clinical services. The organizational structure includes regional and local leadership teams managing individual cancer centers.
Top Products and Market Share
Key Offerings
- Medical Oncology Services: Chemotherapy, immunotherapy, targeted therapies, and other medical treatments for various types of cancer. Market share information is difficult to pinpoint precisely due to the fragmented nature of the cancer care market, but TOI focuses on specific geographic regions. Competitors include large hospital systems and other independent oncology practices.
- Radiation Oncology Services: Radiation therapy for cancer treatment. Market share is localized. Competitors: Larger hospital systems, independent radiation oncology centers.
- Hematology Services: Diagnosis and treatment of blood disorders, including leukemia, lymphoma, and myeloma. The fragmented market makes it difficult to pinpoint specific market share, competition includes hospital and other hematology groups.
Market Dynamics
Industry Overview
The oncology industry is characterized by increasing cancer incidence, advancements in treatment options, and a shift towards value-based care models. The market is highly competitive and driven by innovation, research, and regulatory approvals. Growing demand for convenient, community-based cancer care contributes to the overall market growth.
Positioning
TOI aims to differentiate itself by providing integrated, community-based cancer care services, with a strong focus on value-based care. Their approach is designed to enhance patient access, improve outcomes, and reduce healthcare costs. Their competitive advantage lies in their localized presence and value-based care initiatives.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. TOI's TAM is a subset of this, focused on the community-based cancer care segment and specific geographic regions. Their positioning allows them to capture a share of this TAM by offering comprehensive care and participating in value-based programs.
Upturn SWOT Analysis
Strengths
- Community-based care model
- Focus on value-based care
- Integrated service offerings
- Strong physician network
Weaknesses
- Dependence on Medicare and Medicaid reimbursements
- Limited geographic reach
- Competition from larger hospital systems
- Relatively small compared to competitors
Opportunities
- Expansion into new geographic markets
- Growth in value-based care programs
- Acquisitions of smaller oncology practices
- Partnerships with hospitals and other healthcare providers
Threats
- Changes in healthcare regulations and reimbursement policies
- Increased competition from other oncology providers
- Technological advancements that disrupt existing care models
- Economic downturns that reduce patient access to care
Competitors and Market Share
Key Competitors
- USON
- HCA
- COTY
Competitive Landscape
The competitive landscape is highly fragmented, with competition coming from larger hospital systems, academic medical centers, and other independent oncology practices. TOI's advantages lie in its community-based care model, focus on value-based care, and integrated service offerings. Its disadvantages include its limited geographic reach and smaller scale compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: TOI's historical growth has been driven by expanding its network of cancer centers and increasing patient volume. Their participation in value-based care programs has also contributed to growth by improving outcomes and reducing costs.
Future Projections: Future growth projections depend on factors such as market expansion, regulatory changes, and competitive dynamics. Analyst estimates would be used to evaluate expectations for future growth.
Recent Initiatives: Recent initiatives include expanding their geographic footprint, investing in technology to improve care delivery, and participating in new value-based care programs.
Summary
The Oncology Institute (TOI) is a relatively small player in the fragmented oncology market, focused on community-based and value-based care. Its strengths lie in its integrated services and physician network, but it faces challenges due to its limited geographic reach and dependence on reimbursements. The company is working on expansion and strategic partnerships to improve its market position and should be mindful of regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may not be precise. Financial performance is subject to change based on company performance and market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Oncology Institute Inc
Exchange NASDAQ | Headquaters Cerritos, CA, United States | ||
IPO Launch date 2020-06-04 | CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 825 | Website https://theoncologyinstitute.com |
Full time employees 825 | Website https://theoncologyinstitute.com | ||
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.